In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Barr, Galen sign agreements for drug rights

12 May 2004

Executive Summary

Galen Holdings PLC (women's health care and dermatology products) licensed generic drug company Barr Laboratories exclusive US and Canadian marketing rights to its Loestrin oral contraceptives for $45mm. Galen will also settle Barr's legal challenge to the patents on Galen's femhrt and Estrostep by giving Barr a nonexclusive license to make generic versions six months before their patents expire.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By